OVERVIEW
A Phase 1b Open-Label, Proof of Concept Study to Evaluate the Safety and Efficacy of Novel Hepatitis B Virus (HBV) Combination Therapies in Chronic Hepatitis B (CHB) Subjects Lead Sponsor: Gilead Sciences
PROTOCOL SUMMARY
The primary objective of this study is to evaluate the safety, tolerability, and efficacy of study treatment(s) in virally-suppressed participants with chronic hepatitis B (CHB) infection on oral nucleos(t)ide(s).
Participation requirements
Age
18 Years - 65 Years
Sex
All
Healthy Volunteers
No
Study details
Medical Condition
Chronic Hepatitis B
Gender
N/A
Date
January 2019 - October 2021
Study Type
Interventional
Study Phase
Phase 1b
Product
LDV/SOF, nivolumab, SLGN, and GS-4224
Join Gilead Trial Connect and help advance clinical research. Your participation is key to developing future treatments.
Share Trial